
STERIS (STE) Stock Forecast & Price Target
STERIS (STE) Analyst Ratings
Bulls say
Steris is well positioned by resilient demand across Healthcare Services, AST, and Life Sciences, with 2Q organic growth of 8.1% and FQ1-27 organic growth of 6.2% showing durable underlying momentum. Margin execution is also strong, as adjusted operating margin reached 24.6% in 2Q and 23.8% in FQ1-27, while EPS beat expectations and management maintained FY26 and FY27 growth guidance, signaling confidence in the runway. Additional upside comes from improving late-quarter demand, backlog strength in healthcare equipment, and the planned Xodus Medical acquisition, which is expected to add growth, margins, and EPS once completed by end of CY26.
Bears say
Steris is exposed to a negative setup because its earnings and valuation depend heavily on procedure volumes, capital equipment spending, and steady global healthcare demand, all of which can weaken if spending slows. The company also faces meaningful external risks from unfavorable tariff policy changes, supply chain disruptions, and inflationary pressures, while its exposure to new FDA regulatory actions adds another layer of uncertainty. Given its concentration in healthcare services and sterilization-related businesses, any disruption to hospital purchasing or biopharma demand could pressure revenue growth, margins, and operating visibility.
This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About STERIS (STE) Forecast
STERIS (STE) Analyst Forecast & Price Prediction
Start investing in STERIS (STE)
Order type
Buy in
Order amount
Est. shares
0 shares